Iram Ahmed, MD
Internal Medicine · Lombard, ILNPI 1639383631
Payments from drug & device makers
Across 278 payments — averaging $22.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- AbbVie$896
- Novo Nordisk$828
- Amgen$472
- Pfizer$439
- Astellas Pharma US Inc$347
- plus $2K from 32 others
What the payments were for
- Food & beverage$5,96596%
- Education$2444%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 36 | $1,090 |
| AbbVie(2 entities) | 45 | $896 |
| Novo Nordisk | 38 | $828 |
| Amgen | 25 | $472 |
| Pfizer | 27 | $439 |
| Astellas Pharma US Inc | 11 | $347 |
| Dexcom, Inc. | 11 | $211 |
| Novartis | 10 | $181 |
| Lilly USA, LLC | 8 | $143 |
| Inari Medical, Inc. | 1 | $140 |
| Bayer | 3 | $133 |
| GSK | 6 | $125 |
| Intuity Medical Inc | 1 | $124 |
| Sanofi-aventis U.S. LLC | 3 | $113 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $110 |
| Amarin Pharma, Inc. | 7 | $106 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $78 |
| Sumitomo Pharma America, Inc. | 3 | $78 |
| Xeris Pharmaceuticals, Inc. | 3 | $56 |
| Boehringer Ingelheim | 2 | $51 |
| Idorsia Pharmaceuticals US Inc | 2 | $45 |
| Merck | 3 | $42 |
| Abbott | 2 | $41 |
| Avanir Pharmaceuticals, Inc. | 2 | $40 |
| Cardiva Medical, Inc. | 1 | $37 |
| Redhill Biopharma Inc. | 2 | $35 |
| Sunovion Pharmaceuticals Inc. | 2 | $34 |
| Exact Sciences | 1 | $25 |
| E.r. Squibb & Sons, L.L.C. | 1 | $23 |
| Almatica Pharma LLC | 1 | $23 |
| Ultragenyx Pharmaceutical Inc. | 1 | $22 |
| Sanofi Pasteur Inc. | 1 | $22 |
| Neurocrine Biosciences, Inc. | 1 | $19 |
| Kerecis Limited | 1 | $19 |
| Lundbeck LLC | 1 | $19 |
| Hologic Sales And Service, LLC | 1 | $16 |
| IBSA Pharma Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,209 in reported general payments places this provider in the 90th percentile of 5,182 internal medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 178 | $131,533 |
| NuplazidPimavanserin Tartrate | 48 | $63,538 |
| JanuviaSitagliptin Phosphate | 95 | $62,021 |
| TrulicityDulaglutide | 49 | $61,541 |
| FarxigaDapagliflozin Propanediol | 103 | $54,605 |
| EliquisApixaban | 143 | $51,179 |
| OzempicSemaglutide | 39 | $47,925 |
| EntrestoSacubitril/Valsartan | 124 | $34,397 |
| MyrbetriqMirabegron | 68 | $25,936 |
| Dimethyl Fumarate | 11 | $25,811 |
| TradjentaLinagliptin | 111 | $19,167 |
| XareltoRivaroxaban | 24 | $17,108 |
| MounjaroTirzepatide | 15 | $15,395 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $12,908 |
| LokelmaSodium Zirconium Cyclosilicate | 12 | $12,455 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $51 | $150,700289 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $143 | $76,93664 claims |
| AstraZenecaFarxiga, Lokelma, Symbicort | $1,090 | $71,261130 claims |
| MerckJanuvia | $42 | $62,02195 claims |
| PfizerEliquis | $439 | $51,179143 claims |
| Novo NordiskOzempic | $828 | $47,92539 claims |
| NovartisEntresto | $181 | $34,397124 claims |
| GSKTrelegy Ellipta, Shingrix, Breo Ellipta, Anoro Ellipta | $125 | $33,731109 claims |
| Johnson & JohnsonXarelto, Invokana | $12 | $29,53041 claims |
| Astellas Pharma US IncMyrbetriq | $347 | $25,93668 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $78 | $6,82936 claims |
| AbbVieCombigan | $896 | $2,94713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,182 internal medicine providers in Illinois.
Other internal medicine in Lombard
- Yoko MomoyamaLombard$1.6M
- Karim YunezLombard$119K
- Dennis LevinsonChicago$25.3M
- Mary BrownRockford$16M
- Andrew BartlettChampaign$4.1M
- Danny SugimotoChicago$4M
- Peter O DonnellChicago$3.9M
- Daniel CatenacciChicago$3.5M
- Jeffrey GeohasEvanston$2.3M
- Patricia WalshChicago$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.